Marta Valenciano

Summary

Publications

  1. ncbi First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States
    M Valenciano
    EpiConcept, Health Information System, Paris, France
    Euro Surveill 13:. 2008
  2. ncbi I-MOVE: a European network to measure the effectiveness of influenza vaccines
    M Valenciano
    EpiConcept, Paris, France
    Euro Surveill 17:. 2012
  3. doi The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2)
    Marta Valenciano
    Epidemiology Department, EpiConcept, Paris, France Electronic address
    Vaccine 33:2813-22. 2015
  4. ncbi Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13
    M Valenciano
    EpiConcept, Paris, France
    Euro Surveill 18:3. 2013
  5. doi Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks
    Marta Valenciano
    EpiConcept, Paris, France
    Vaccine 28:7381-8. 2010
  6. pmc Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
    Marta Valenciano
    EpiConcept, Paris, France
    PLoS Med 8:e1000388. 2011
  7. doi I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
    Esther Kissling
    EpiConcept, Paris, France
    Euro Surveill 21:. 2016
  8. pmc I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe
    Esther Kissling
    EpiConcept, Paris, France
    PLoS ONE 6:e27622. 2011
  9. doi Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15
    Marta Valenciano
    Epidemiology Department, EpiConcept, Paris, France
    Euro Surveill 21:pii=30139. 2016

Collaborators

Detail Information

Publications9

  1. ncbi First steps in the design of a system to monitor vaccine effectiveness during seasonal and pandemic influenza in EU/EEA Member States
    M Valenciano
    EpiConcept, Health Information System, Paris, France
    Euro Surveill 13:. 2008
    ..The pilot studies will be the basis for the development of robust methods to monitor IVE in EU/EEA MS...
  2. ncbi I-MOVE: a European network to measure the effectiveness of influenza vaccines
    M Valenciano
    EpiConcept, Paris, France
    Euro Surveill 17:. 2012
    ..The scientific knowledge and experience in practical, managerial and logistic issues can be adapted to monitor surveillance of the effectiveness of other vaccines...
  3. doi The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogenous results by country against A(H3N2)
    Marta Valenciano
    Epidemiology Department, EpiConcept, Paris, France Electronic address
    Vaccine 33:2813-22. 2015
    ..Influenza A(H3N2) and A(H1N1)pdm09 viruses co-circulated during the season...
  4. ncbi Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13
    M Valenciano
    EpiConcept, Paris, France
    Euro Surveill 18:3. 2013
    ..4% (95% CI: -20.7 to 79.6) against all influenza types in the target groups for vaccination. Efforts to improve influenza vaccines should continue to better protect those at risk of severe illness or complications...
  5. doi Study designs for timely estimation of influenza vaccine effectiveness using European sentinel practitioner networks
    Marta Valenciano
    EpiConcept, Paris, France
    Vaccine 28:7381-8. 2010
    ..Results from practitioner-based studies complement other pieces of evidence (e.g. immunogenicity studies, vaccine efficacy, surveillance data) to assess the effect of influenza vaccination in the population...
  6. pmc Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study
    Marta Valenciano
    EpiConcept, Paris, France
    PLoS Med 8:e1000388. 2011
    ....
  7. doi I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?
    Esther Kissling
    EpiConcept, Paris, France
    Euro Surveill 21:. 2016
    ..7% (95% CI: 51.3-82.4) 44 days after vaccination to 21.4% (95% CI: -57.4-60.8) at season end. To assess if vaccination campaign strategies need revising more evidence on VE by time since vaccination is urgently needed. ..
  8. pmc I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe
    Esther Kissling
    EpiConcept, Paris, France
    PLoS ONE 6:e27622. 2011
    ....
  9. doi Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15
    Marta Valenciano
    Epidemiology Department, EpiConcept, Paris, France
    Euro Surveill 21:pii=30139. 2016
    ..6 to 71.2) among those aged 0-14, 15-59 and ≥60 years respectively. VE against A(H1N1)pdm09 and B was moderate. The low VE against A(H3N2) is consistent with the reported mismatch between circulating and vaccine strains. ..